Description
Anti-TGF beta 2 Antibody, Highly Galactosylated (BioBet-GA-456ZP) is a human IgG4 antibody against TGF beta 2 which contains with a high level of galactosylation.
Antibody Indication
Glaucoma surgery
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced TGF beta 2 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
TGFB2
Full Name
TGFB2 Gene(Protein Coding)
Transforming Growth Factor Beta 2
Background
This gene encodes a secreted ligand of the TGF-beta (transforming growth factor-beta) superfamily of proteins. Ligands of this family bind various TGF-beta receptors leading to recruitment and activation of SMAD family transcription factors that regulate gene expression. The encoded preproprotein is proteolytically processed to generate a latency-associated peptide (LAP) and a mature peptide, and is found in either a latent form composed of a mature peptide homodimer, a LAP homodimer, and a latent TGF-beta binding protein, or in an active form consisting solely of the mature peptide homodimer. The mature peptide may also form heterodimers with other TGF-beta family members. Disruption of the TGF-beta/SMAD pathway has been implicated in a variety of human cancers. A chromosomal translocation that includes this gene is associated with Peters' anomaly, a congenital defect of the anterior chamber of the eye. Mutations in this gene may be associated with Loeys-Dietz syndrome. This gene encodes multiple isoforms that may undergo similar proteolytic processing. [provided by RefSeq, Aug 2016]
Alternative Names
Lerdelimumab;Trabio;CAT-152;6B1;Anti-TGF-Beta-2;Trabio;Trabio;CAT-152;TGFB2;transforming growth factor, beta 2;transforming growth factor beta-2;G-TSF;cetermin;polyergin;BSC-1 cell growth inhibitor;glioblastoma-derived T-cell suppressor factor;TGF-beta2;M
Gene ID
7042
UniProt ID
P61812
Cellular Localization
Extracellular region or secreted
Genecards
11768
Involvement in Disease
Its related pathways are Cell adhesion_Plasmin signaling and Degradation of the extracellular matrix.
Related Pathways
1.Transforming growth factor-2 preprotein: Delay associated peptide (LAP) and transforming growth factor-2 (tgf-2) chain precursors, which constitute the regulatory and active subunits of tgf-2, respectively. 2.It is necessary to store the transforming growth factor-2 (tgf-2) chain in a latent state in the extracellular matrix (similarity). It associates non-covalently with tgf-2, and regulates its activation (through similarity) through interaction with "environmental molecules" that control tgf-2 activation (such as LTBP1 and LRRC32/GARP). 3.Transforming growth factor-2: a multifunctional protein that regulates various processes such as angiogenesis and heart development. Activation into the mature form follows different steps: After the cleavage of the preprotein in the Golgi apparatus, the delayed-associated peptide (LAP) and transforming growth factor-2 (tgf -2) chains remain non-covalently linked, making tgf -2 in the extracellular matrix Inactivation during storage (due to similarity). At the same time, the LAP chain interacts with "environmental molecules", such as LTBP1 and LRRC32/GARP, to control the activation of tgf-2 and keep it latent in the extracellular environment (similar). Once activated after the release of LAP, tgf-2 acts by binding to tgf-receptors (TGFBR1 and TGFBR2) and conducts signals (through similarity).
Field of research
The precursor is cleaved into mature TGF-beta-2 and LAP, which remains non-covalently linked to mature TGF-beta-2 rendering it inactive.
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG4
Antibody Clone
BioBet-GA-456ZP
Description
The Highly Galactosylated Anti-TGF beta 2 (Lerdelimumab), a biobetter antibody contains with a high level of galactosylation.
Antibody Indication
Glaucoma surgery
